Shanghai MicroPort MedBot Group (2252) H2 2025 earnings summary

Executive summary

• Revenue surged 114.2% year-over-year to RMB551.1 million, driven by rapid commercialisation of the Toumai laparoscopic surgical robot and robust overseas expansion, with overseas sales accounting for 73% of total revenue.

• Net loss narrowed by 60.7% to RMB254.1 million, with adjusted net loss down 65.8% to RMB165.0 million, reflecting higher gross profit, reduced operating expenses, and improved R&D efficiency.

• Gross profit rose 209.2% to RMB266.6 million, with gross margin improving from 34% to 48% due to cost reductions and production efficiencies.

• Major product Toumai achieved over 100 new overseas orders, with global installations exceeding 140 units and certifications in over 60 countries.

• The company maintained strong R&D momentum, launching new products and achieving breakthroughs in remote and autonomous surgery technologies.

Financial highlights

• Revenue: RMB551.1 million (+114.2% YoY); Gross profit: RMB266.6 million (+209.2% YoY).

• Net loss: RMB254.1 million (vs. RMB647.1 million prior year); Adjusted net loss: RMB165.0 million (vs. RMB482.6 million prior year).

• Gross margin: 48% (up from 34%); Selling and marketing expenses: RMB203.6 million (36.9% of revenue, down from 80.8%).

• R&D costs: RMB216.0 million (-30.0% YoY); Administrative expenses: RMB45.6 million (-17.5% YoY).

• Free cash outflow narrowed to RMB63 million (from RMB388 million); cash and equivalents at RMB636.3 million.

• Interest-bearing borrowings reduced to RMB389.1 million (from RMB634.5 million); debt-to-asset ratio improved to 70%.

Outlook and guidance

• Plans to strengthen product portfolio, accelerate commercialisation, and expand global presence.

• Focus on multi-specialty surgical platforms, training centres, and partnerships with top hospitals and research institutions worldwide.